In this educational program, which was held at the ESC Congress 2017 in Barcelona, Spain, epigenetic regulation of gene expression in patients at high CV risk with diabetes was reviewed

Prof Nicholls shared some insights from the first human trials on epigenetic approaches to treat CVD. More specifically, he summarized the findings from the first trials with apabetalone.

Prof Stroes explained epigenetics and epigenetic modulation. Moreover, he summarized data from studies with apabetalone, a BET inhibitor, and the first trial results with apabetalone.

This summary of the presentation by Prof Ray gives insight in the high CV risk in patiens with diabetes. Treatment options and testing of these drugs in trials were discussed, including the new antidiabetic drugs, such as empagliflozin, and other novel agents, such as the PCSK9 inhibitor evolocumab.

This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017

This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017

This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017